Implicity secures $40M growth equity funding to scale its AI-driven cardiac monitoring platform globallyCAMBRIDGE, Mass. and PARIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Implicity, a global leader in AI-driven cardiac remote monitoring, has secured a $40 million funding round led by European tech growth capital firm IRIS, alongside Five Arrows, the alternative assets arm of Rothschild & Co.
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA ClearanceCloud-based AI algorithm supports implantable cardiac monitors from all major manufacturers, reducing false-positive alerts by up to 76% while maintaining high sensitivity for true events
Study Shows Implicity’s New Agnostic Cloud-Based AI Algorithm Further Reduces False Alerts Even After Manufacturer AI Filtering in Modern DevicesNew HRS data extends EHRA findings with a specific analysis of next-gen ILRs, demonstrating that, on top of manufacturer-embedded AI, Implicity filters out 61.6% of false positives while maintaining 98.3% sensitivity
EHRA 2026 Studies Reveal Why False Positives Persist in AI-Equipped Implantable Cardiac MonitorsResearch identifies guideline-based interpretation gaps and signal-detection issues behind non-actionable alerts and shows how an additional cloud-based AI layer can significantly reduce clinician review burden while maintaining high sensitivity
